PMID- 12088743
OWN - NLM
STAT- MEDLINE
DCOM- 20020903
LR  - 20190712
IS  - 0306-4522 (Print)
IS  - 0306-4522 (Linking)
VI  - 112
IP  - 4
DP  - 2002
TI  - Osmotic stress increases brain-derived neurotrophic factor messenger RNA 
      expression in the hypothalamic supraoptic nucleus with differential regulation of 
      its transcripts. Relation to arginine-vasopressin content.
PG  - 841-50
AB  - We have shown that osmotic stress increases brain-derived neurotrophic factor 
      (BDNF) mRNA in the supraoptic nucleus and that this increase seems to be 
      determined by the high expression of transcripts containing exon I. The 
      paraventricular nucleus is another hypothalamic neuronal subset where BDNF mRNA 
      is also sensitive to osmotic stress stimulation. In this nucleus, transcripts 
      containing exon I were not modified but only those containing exon II. By 
      contrast, transcripts containing exon III did not exhibit any variation in our 
      experimental conditions. The presence of BDNF mRNA in both paraventricular and 
      supraoptic hypothalamic nuclei was recently reported. These nuclei are extremely 
      sensitive to osmotic stimuli and their neurons secrete oxytocin and 
      arginine-vasopressin in the posterior pituitary gland. This study was thus 
      designed to investigate the possible involvement of BDNF in the response of 
      supraoptic nucleus to osmotic stress stimulus. Osmotic stress was induced by 
      hypertonic saline injection (1.35% NaCl) administered to animals 3 h before 
      analysis. We used non-isotopic in situ hybridization to study the expression of 
      BDNF mRNA and its transcripts with antisense riboprobes on histological brain 
      sections, including paraventricular and supraoptic nuclei from control and 
      osmotic stress-stimulated animals. To investigate a possible correlation between 
      the expression of BDNF mRNA and arginine-vasopressin, the peptide content was 
      analyzed by immunohistochemistry in both paraventricular and supraoptic nuclei at 
      two different times after hyperosmotic injection. The results showed that BDNF 
      mRNA expression preceded the arginine-vasopressin increase. In addition, on 
      serial adjacent histological sections of supraoptic nucleus (10 microm), both 
      BDNF and arginine-vasopressin mRNAs were visualized by isotopic in situ 
      hybridization and the images were overlaid, showing that almost all of the 
      hybridization signals were overlapped. Taken together our results are in keeping 
      with the hypothesis that activation of the different BDNF promoters seems to be 
      region-specific. Besides, the temporal correlation between both BDNF mRNA 
      expression and arginine-vasopressin content, as well as the morphological 
      vicinity between their respective producing cells in the supraoptic nucleus, 
      suggest an autocrine or paracrine action for this neurotrophin in the regulation 
      of arginine-vasopressin secretion.
FAU - Aliaga, E
AU  - Aliaga E
AD  - Laboratoire de Plasticite Cerebrale, UMR 5102 CNRS, Universite Montpellier 2, CC 
      090, Place Eugene Bataillon, 34095 Montpellier Cedex 5, France. 
      stbanaliaga@yahoo.com
FAU - Arancibia, S
AU  - Arancibia S
FAU - Givalois, L
AU  - Givalois L
FAU - Tapia-Arancibia, L
AU  - Tapia-Arancibia L
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Neuroscience
JT  - Neuroscience
JID - 7605074
RN  - 0 (Brain-Derived Neurotrophic Factor)
RN  - 0 (RNA, Messenger)
RN  - 0 (Saline Solution, Hypertonic)
RN  - 113-79-1 (Arginine Vasopressin)
SB  - IM
MH  - Animals
MH  - Arginine Vasopressin/*metabolism
MH  - Brain-Derived Neurotrophic Factor/genetics/*metabolism
MH  - Exons
MH  - Immunohistochemistry
MH  - In Situ Hybridization
MH  - Injections
MH  - Male
MH  - Osmotic Pressure
MH  - Paraventricular Hypothalamic Nucleus/metabolism
MH  - RNA, Messenger/*metabolism
MH  - Rats
MH  - Rats, Sprague-Dawley
MH  - Saline Solution, Hypertonic
MH  - Supraoptic Nucleus/*metabolism
MH  - Time Factors
MH  - Up-Regulation
EDAT- 2002/06/29 10:00
MHDA- 2002/09/11 10:01
CRDT- 2002/06/29 10:00
PHST- 2002/06/29 10:00 [pubmed]
PHST- 2002/09/11 10:01 [medline]
PHST- 2002/06/29 10:00 [entrez]
AID - S0306452202001288 [pii]
AID - 10.1016/s0306-4522(02)00128-8 [doi]
PST - ppublish
SO  - Neuroscience. 2002;112(4):841-50. doi: 10.1016/s0306-4522(02)00128-8.